The primary audience for the good participatory practice guidelines for emerging pathogens (GPP-EP, December 2016) is all those involved in designing, financing, and implementing prevention and treatment trials of emerging or re-emerging pathogens. These are pathogens that are causing or are likely to cause severe outbreaks in the near future and for which few or no medical countermeasures exist. They include diseases such as COVID-19, Ebola virus disease, Crimean Congo haemorrhagic fever, Marburg, Lassa fever, MERS and SARS coronavirus diseases, Nipah, Rift Valley fever, Chikungunya, severe fever with thrombocytopaenia syndrome, Zika, and other known and as yet unknown pathogens.
This guidance specifically addresses good participatory practices during trials conducted in health emergency contexts where accelerated research processes are needed.
GPP-EP provide trial sponsors and research team members with principle-based guidance on how to effectively engage stakeholders in the design and conduct of prevention and treatment trials for emerging and reemerging pathogens. The guidelines outline stakeholder engagement activities required for the development, planning, implementation, conclusion, and results dissemination of trials conducted in emergency or crisis settings. The guidelines support greater attention to the interests of all stakeholders affected by an emerging pathogen toward a mutual understanding of meaningful stakeholder engagement in research. They help establish shared standards, expectations, and accountability for effective and outcome-driven engagement throughout all phases of emerging pathogen trials.
Download the WHO GPP-EP [PDF] HERE
This work is licensed under a Creative Commons Attribution 4.0 International License